I2I
BMY icon

Insight 2811 Inc’s Bristol-Myers Squibb BMY Stock Holding History

Insight 2811 Inc’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,900
Closed -$85K – 107
2013
Q2 		$85K Buy
+1,900
New +$82.5K 0.05% 130

Other funds holding BMY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Insight 2811 Inc's BMY Position: Q3 2013 in Review

Insight 2811 Inc sold out of Bristol-Myers Squibb (BMY) in Q3 2013, closing a stake of 1,900 shares — an estimated $85K sold.

Insight 2811 Inc first reported a position in BMY in Q2 2013 and held it in 1 quarter. The position peaked at $85K in Q2 2013. 1,187 funds tracked by Wall St. Rank hold BMY as of Q3 2013.

  • Insight 2811 Inc reported no remaining Bristol-Myers Squibb position as of Q3 2013 after selling out during the quarter.
  • Insight 2811 Inc sold 1,900 Bristol-Myers Squibb shares in Q3 2013, an estimated $85K.
  • Insight 2811 Inc first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 1 quarter.
  • Insight 2811 Inc's Bristol-Myers Squibb position peaked at $85K in Q2 2013.
  • 1,187 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2013.

Based on Insight 2811 Inc's 13F filing for Q3 2013, filed 4 Nov 2013.